| May 1 |
VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque |
| May 1 |
Excess Oral Doses of Acurox Tablets are Disliked by Subjects with a History of Opioid Abuse |
| May 4 |
Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien Study at ARVO 2009 Annual Meeting |
| May 4 |
Tranzyme Pharma's Successful Phase 2 Postoperative Ileus Trial Results to be Presented at the American Society of Colon and Rectal Surgeons 2009 Annual Meeting |
| May 4 |
Onset Therapeutics Announces Release of Study Results Demonstrating That ANESTAFOAM (Lidocaine 4% Foam) Reduces Pain Associated with Common Dermatologic Procedures |
| May 4 |
Rexahn Reports Positive Preliminary Findings in Zoraxel Clinical Trial to Treat Erectile Dysfunction |
| May 4 |
SuperGen's MP-470 Demonstrates Clinical Benefit in Lung Cancer Patients |
| May 4 |
TransMolecular Presents New Information on Distinct Anti-Angiogenic Mechanism-of-Action of TM601 |
| May 4 |
Narcolepsy is an Autoimmune Disorder, Stanford Researcher Says |
| May 4 |
Fovea Reports Positive Results with Prednisporin in Persistent Allergic Conjunctivitis |
| May 4 |
Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial |
| May 4 |
Discovery Labs' KL4 Surfactant Shows Physiologic and Survival Benefit in a Preclinical Model for Severe Respiratory Condition -- Acute Lung Injury |
| May 4 |
Inspire Announces Poster Presentations at 2009 Association for Research in Vision and Ophthalmology Annual Meeting |
| May 4 |
Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology |
| May 4 |
Pulmo BioTech Inc. Announces Paper to be Presented at Symposium |
| May 4 |
Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR Clinical Study |
| May 4 |
Rexahn Reports Positive Preliminary Phase IIa Findings in Zoraxel Clinical Trial to Treat Erectile Dysfunction |
| May 4 |
Sciele Pharma and Plethora Solutions Announce Encouraging Results from European Phase III Study on PSD502 |
| May 4 |
First Oral Drug for Uveitis Reduces Both Inflammation and Recurrence Rate in Potentially Blinding Eye Disease, Reports Lux Biosciences |
| May 4 |
Positive Results for Ophthotech's Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome |
| May 4 |
Results Shown in BioCancell Compassionate Use Trial Using BC-819 for Treatment of Renal Cancer |
| May 5 |
Northlich Wins Eight Healthcare Advertising Awards and Three Aster Awards for Outstanding Marketing Campaigns |
| May 5 |
New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel |
| May 5 |
NicOx co-presents four posters on PF-03187207 for glaucoma at ARVO with Pfizer Inc |
| May 5 |
Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients |
| May 5 |
New Study Shows Women Experience Significantly Less Unscheduled Bleeding With the ORTHO TRI-CYCLEN(R) LO Birth Control Pill Versus Another Pill |
| May 6 |
Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB |
| May 6 |
Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome |
| May 6 |
Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples |
| May 6 |
Metabasis Therapeutics Announces Late-Breaking Abstract on MB07803 Trial Results Accepted for Presentation at the American Diabetes Association Meeting |
| May 6 |
BioInvent Reports Positive Phase I Results for BI-204, in Development for Prevention of Cardiovascular Conditions Associated with Atherosclerosis |
| May 6 |
Creative MediaWorks Goes Platinum! |
| May 6 |
Hypertension: Information Technology to Improve Blood Pressure |
| May 6 |
Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases |
| May 6 |
Pharmaceutical Promotion At Its Productivity Frontier |
| May 6 |
Lipoxen Positive Ph I EPO Trial Results |
| May 6 |
Inotek Pharmaceuticals Presents Preclinical Data in Support of Novel Glaucoma Candidate, INO-8875 at ARVO |
| May 6 |
SCORR Marketing Named Agency of Record by Skilled Care Pharmacy |
| May 6 |
Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting |
| May 6 |
Burzynski Research Institute Announces Positive Results of Phase II ANP Clinical Trial |
| May 7 |
Analyses of phase 3 blood pressure data for N icOx -- naproxcinod presented at ASH |
| May 7 |
Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine |
| May 7 |
Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy |
| May 7 |
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity |
| May 7 |
Results at ASCO Congress 2009 Highlight Merck's Leadership in Personalizing Cancer Care |
| May 7 |
ISTA Pharmaceuticals Highlights Bepreve Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting |
| May 7 |
ADVENTRX Announces Results From ANX-514 Bioequivalence Study |
| May 8 |
Archimedes Pharma announces ground breaking phase III data showing NasalFent to be superior to the standard of care for breakthrough cancer pain |
| May 8 |
New study results further support the evidence that the HPV vaccine Gardasil will provide long-lasting protection |
| May 8 |
The four-type HPV vaccine Gardasil demonstrates real life benefits |
| May 8 |
Studies of Gardasil, Merck's Cervical Cancer Vaccine, and HPV 16 Vaccine Component of Gardasil Presented at International Papillomavirus Conference |
| May 8 |
New Data for GlaxoSmithKline’s Vaccine, Cervarix, Presented at IPV Conference |
| May 8 |
Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results |
| May 8 |
Photo: Levemir Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in Titrate Study |
| May 8 |
Rapaflo (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days |
| May 8 |
New Data Shows Blood Pressure Reduction Therapy with Benicar and Benicar HCT Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure |
| May 8 |
New Data Shows Azor (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure |
| May 8 |
Juvaris BioTherapeutics' Universal Influenza Vaccine Protects from Lethal H1N1 and H3N2 Challenges in Pre-Clinical Studies |
| May 11 |
AstraZeneca Announces Top Line Results From Pivotal Phase III Study for Brilinta |
| May 11 |
Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS Liberte Stent |
| May 12 |
Gilead Sciences' Phase III Darusentan Data Show Significant Blood Pressure Reductions in Resistant Hypertension Patients |
| May 12 |
Angiotech and Boston Scientific welcome journal article noting important differences between drug-eluting stent brands |
| May 12 |
Data From Meta-Analysis Show Clinical Pregnancy Rate With Vaginal Progesterone is Comparable With Intramuscular Progesterone When Administered at Optimal Dosing in Infertility Patients |
| May 13 |
Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for Euflexxa for the Treatment of Osteoarthritis Knee Pain |
| May 13 |
ZymoGenetics Reports Encouraging Preliminary Results from Phase 2 Study of IL-21 in Metastatic Melanoma Conducted by NCIC |
| May 13 |
AlphaVax Announces Promising Results in Melanoma Studies |
| May 13 |
Pfizer to Present New Clinical Data Highlighting Customized Treatment Approaches For Difficult-To-Treat Cancers |
| May 14 |
Mesoblast Limited (ASX:MSB) Announce Heart Muscle Function Improved Significantly After Single, Lowest-Dose Injection Of "Off-The-Shelf" Stem Cells In Patients With Heart Failure |
| May 14 |
STINSON Brand Innovation, Inc. Celebrates 5 Years in Business |
| May 14 |
Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS |
| May 14 |
Synta Announces Elesclomol Phase 3 Melanoma Data to be Featured in Oral Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| May 14 |
Aradigm Presents Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis at 2009 International Conference of the American Thoracic Society |
| May 14 |
Benefits of Catheter Ablation with the NAVISTAR THERMOCOOL Catheter Sustained for One Year in the Treatment of Symptomatic, Paroxysmal Atrial Fibrillation |
| May 14 |
Study Shows Chemotherapy Improves Survival Among Older Breast Cancer Patients |
| May 14 |
Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa |
| May 15 |
Antares Pharma and Population Council Announce Preliminary Positive Phase 2 Trial Results |
| May 15 |
Data from the Phase III SATURN Study Show Tarceva Improved Progression-Free Survival When Used as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer |
| May 15 |
Concordia Pharmaceuticals Reports Encouraging Clinical Data in Patients with K-Ras Mutations Treated with First-in-Class Ras Antagonist, Salirasib |
| May 15 |
SPRYCEL (Dasatinib) Shows Potential as Treatment for Prostate Cancer |
| May 15 |
OSI Pharmaceuticals Provides Update on OSI-906 Data Being Presented on May 30th at the Upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| May 16 |
Biotec Pharmacon ASA (NO) - Interim results for the first quarter 2009 |
| May 18 |
VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients |
| May 18 |
APF530 Phase 3 Data for Chemotherapy-Induced Nausea and Vomiting to be Presented at American Society of Clinical Oncology 2009 Annual Meeting |
| May 18 |
BioLineRx Presents Data Demonstrating the Potential for BL-1020 to Improve Cognitive Deficits in Preclinical Models at Society of Biological Psychiatry 64rd Annual Scientific Convention & Meeting and Provides EAGLE Phase 2b Update |
| May 18 |
Can-Fite Announces Positive Results From Its Phase II Trial Treating Keratoconjunctivitis Sicca (Dry Eye Syndrome) With CF101 |
| May 18 |
Altair Therapeutics Reports Successful Completion of Phase I Study of Inhaled AIR645 |
| May 18 |
Ardea Biosciences to Present Preclinical and Phase 1 Data on its Lead Gout Product Candidate, RDEA594, at the Annual European Congress of Rheumatology |
| May 18 |
Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis |
| May 18 |
ImmunoGen, Inc. Announces Trastuzumab-DM1 Presentations at the 2009 American Society for Clinical Oncology Annual Meeting |
| May 18 |
Amgen Highlights Data to Be Presented at ASCO |
| May 18 |
Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting |
| May 18 |
Shire Announces Study Results of the Effects of INTUNIV (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms |
| May 18 |
BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting |
| May 18 |
EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting |
| May 18 |
Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US |
| May 18 |
Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology |
| May 19 |
Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes |
| May 19 |
Two Targeted Therapies Likely Better Than One in Patients with Aggressive Lymphoma, Mayo Clinic Researchers Say |
| May 19 |
Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections |
| May 19 |
Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting |
| May 19 |
Santhera's US Phase III IONIA Trial in Friedreich's Ataxia Misses Primary Endpoint |
| May 19 |
AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting |
| May 19 |
ChemoCentryx's Traficet-EN Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week |
| May 19 |
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009 |
| May 19 |
Provectus Reports on Presentation of Chemoablation of Metastatic Melanoma from Joint Meeting of 7th World Congress on Melanoma and 5th Congress of the European Association of Dermato-Oncology |
| May 19 |
Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting |
| May 19 |
Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference |
| May 19 |
NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial |
| May 19 |
Dynavax Announces Data Presentations at American Thoracic Society Medical Conference |
| May 19 |
New Data from ENDEAVOR-II Challenges Conventional Wisdom on Drug-Eluting Stents |
| May 19 |
In Patients with Heart Attacks, CYPHER Sirolimus-Eluting Coronary Stent Results Sustained out to Four Years Compared to Bare Metal Stents |
| May 19 |
Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain |
| May 19 |
Altair Therapeutics Reports Successful Completion of phase I study of Inhaled AIR645 |
| May 19 |
ATS bosentan in combination with tadalafil |
| May 19 |
Basilea Pharmaceutica Ltd. (CH) - Basilea presents new efficacy data on BAL30072, its novel antibiotic against Gram-negative bacteria |
| May 19 |
Bayer Schering Pharma presents positive results of phase II study with Riociguat |
| May 19 |
Velcade (Bortezomib) for Injection and Pipeline Data to Be Highlighted at American Society of Clinical Oncology Annual Meeting |
| May 19 |
Addition of Lyrica Significantly Improved Generalized Anxiety Disorder Symptoms in Patients Who Responded Only Partially to Previous GAD Treatments |
| May 19 |
Upcoming BioAlliance Pharma's Presentations at International Conferences on Infectious Diseases and Oncology |
| May 19 |
Continued Growth Drives Move at Mc|K Healthcare |
| May 19 |
Kamada Presents New Data on its Alpha-1 Antitrypsin at the American Thoracic Society Annual Meeting |
| May 19 |
Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report |
| May 20 |
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) |
| May 20 |
Blue Spoon Consulting Publishes White Paper: Pharmaceutical Industry Strategy for a Global Economic System |
| May 20 |
Prospect Therapeutics, Inc.'s GCS-100 Exhibits a Low Toxicity Profile in Cancer Patients |
| May 20 |
Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint |
| May 20 |
Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial |
| May 20 |
Results of Phase III Study on Labopharm's Novel Antidepressant Published in Psychiatry (Edgemont) Journal |
| May 20 |
NicOx presents phase 3 quality of life data for naproxcinod at ISPOR |
| May 20 |
Nevo Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial |
| May 21 |
Antisoma plc (UK) - Phase II trial of ASA404 published in Lung Cancer |
| May 21 |
Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia |
| May 21 |
TransMolecular Announces Presentation of Data Highlighting Anti-angiogenic and Tumor-targeting Properties of TM601 at ASCO Annual Meeting |
| May 21 |
Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association |
| May 21 |
Somaxon Pharmaceuticals Presents Analyses of Silenor Clinical Data at the American Psychiatric Association Annual Meeting |
| May 21 |
Phase III Data Show Novartis Investigational Bronchodilator QAB149 Significantly Improves Lung Function Over Current Treatments in COPD |
| May 21 |
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial |
| May 21 |
Abbott's XIENCE V Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study |
| May 21 |
Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data In Patients With Schizophrenia |
| May 21 |
SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS Express2 Stent System |
| May 21 |
PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS |
| May 21 |
Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents |
| May 22 |
Seidler Bernstein Wins Assignment from Microline PENTAX |
| May 22 |
New Data Demonstrate Risperdal Consta (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia |
| May 26 |
Seattle Genetics to Present SGN-35 and Lintuzumab Clinical Data at the European Hematology Association Congress |
| May 26 |
Astex reports positive data from its Phase I study of AT9283 at the ASCO Annual Meeting 2009 |
| May 26 |
Widely Used Cancer Drug Bevacizumab Associated with Significantly Increased Risk of Gastrointestinal Perforation |
| May 26 |
Boceprevir eliminated Hep C virus in unprecedented number of patients |
| May 26 |
The Quality and Purity of Biosimilar Epoetin Zeta (Retacrit) is Demonstrated Through Comparative Analysis with Epoetin Alfa - Presented at WCN 2009 |
| May 26 |
Cytheris Announces Publication of Preclinical Study in Nature Medicine Showing Combination of Interleukin-7 with Viral Vaccine Boosts Immunity to Tumors |
| May 26 |
MAP Pharmaceuticals Phase 3 Trial of Levadex Migraine Product Candidate Meets All Four Primary Endpoints |
| May 26 |
New Study Evaluating the ADHD Medication VYVANSE (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) |
| May 26 |
Medinox Announces Clinical Results of Naproxen Prodrug |
| May 26 |
OSI Pharmaceuticals to Provide a Summary of Data Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting |
| May 26 |
Scientific Data Relating to Cinryze Presented at 6th Annual C1 Inhibitor Deficiency Workshop |
| May 26 |
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO |
| May 26 |
TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009 |
| May 26 |
New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal |
| May 26 |
NanoGuardian Partners with SDI on Closed-Loop Protection |
| May 26 |
Two-Year Data Reinforce Effect of Actemra (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients |
| May 26 |
First in class uveitis therapy -- Ph3 results highlighted at IOIS |
| May 26 |
Proscape Technologies Congratulates Connect Tech, a Division of Draftfcb Healthcare, on Becoming a Gold Certified Content Partner |
| May 27 |
Addex Pharmaceuticals (CH) - Glutamate Receptor "mGluR5" Implicated in GERD |
| May 27 |
Nycomed Reports a Solid Start to 2009 |
| May 27 |
Affymax Reports Phase 2 Clinical Trial Data Supporting Hemoglobin Increases with Once-Per-Month Hematide Regardless of Patient Baseline Renal Function |
| May 27 |
Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorders at Upcoming Conference |
| May 27 |
Oncothyreon announces closing of $11.1 million registered direct financing |
| May 27 |
Tugboat Consulting Group Announces Key Collaborations To Offer Unique Marketing Products |
| May 27 |
CombinatoRx Reports Positive Phase 2 Trial Results for CRx-401 |
| May 27 |
Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease |
| May 27 |
GTC Biotherapeutics Announces One-for-Ten Reverse Stock Split |
| May 27 |
Genta Incorporated Announces Postponement of Special Stockholders Meeting |
| May 27 |
Spectrum Pharmaceuticals to Raise $20 Million from Institutional Investors at $5.11 Per Share, the Closing Bid Price on Tuesday, May 26, 2009 |
| May 27 |
Arno Therapeutics Announces Three Poster Presentations at ASCO Annual Meeting |
| May 27 |
Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week |
| May 27 |
Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting |
| May 27 |
Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009 |
| May 27 |
Genaera Receives Non-Compliance Notice from Nasdaq |
| May 27 |
Sarah Cannon Research Institute to Present Latest Cancer Research Data at National Clinical Oncology Conference |
| May 27 |
Metastatic Colon Cancer: In a Randomized Phase II Clinical Study, Antineoplaston Therapy Doubled the 5-Year Survival Rate Following Curative Resection of Hepatic Metastases |
| May 28 |
SCORR Marketing Wins Nine Awards in National Marketing Competitions |
| May 28 |
Tongjitang Chinese Medicines Company to Announce First Quarter 2009 Financial Results on June 3, 2009 |
| May 28 |
Biofrontera AG (DE) - Biofrontera raised 3 Million Euro in capital round |
| May 28 |
GPC Biotech AG (DE) - GPC Biotech Reports Financial Results for First Quarter 2009 |
| May 28 |
New Study Results Published Compare Abraxane to Taxotere |
| May 28 |
Minster Pharmaceuticals Plc Preliminary Results |
| May 28 |
AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria |
| May 28 |
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types |
| May 28 |
CuraGen to Present CR011-vcMMAE Data at ASCO |
| May 28 |
Peregrine Pharmaceuticals Reports Progress in Cotara Brain Cancer Clinical Program |
| May 28 |
EpiCept Announces Presentation of New Crinobulin Data at 2009 American Society of Clinical Oncology Annual Meeting |
| May 28 |
GTx Announces Toremifene 80 mg Phase III ADT Clinical Trial Data to be Presented at the Annual Meeting of the American Society of Clinical Oncology |
| May 28 |
GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants |
| May 28 |
Oculus Innovative Sciences Announces Fiscal Fourth Quarter Financial Results and Corporate Update Release and Conference Call |
| May 28 |
Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors |
| May 28 |
InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting |
| May 28 |
Dana-Farber Cancer Institute Presents Results of GlycoMimetics' Lead Drug Candidate in Models of Multiple Myeloma at American Society of Clinical Oncology Annual Meeting |
| May 28 |
BioMS Medical to Present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences |
| May 28 |
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer |
| May 28 |
Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million |
| May 28 |
Valeant Plans Senior Notes Offering |
| May 28 |
Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009 |
| May 28 |
Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting |
| May 28 |
Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer |
| May 28 |
MethylGene Reports Favorable Kinase Inhibitor Data at ASCO Meeting |
| May 28 |
Talecris data shows that concentrated form of Prolastin is safe and tolerable; potentially cuts infusion times in half for patients with AAT deficiency |
| May 29 |
Phase 1 Study for Halozyme's Insulin-PH20 Published, Highlights Findings for Faster Acting Insulin Formulations |
| May 29 |
Lipoxen Raises £2.9m, Led by Baxter Plus Director's Dealings |
| May 29 |
Valeant Pharmaceuticals International Sr. Unsecured Debt Ratings Assigned; CCR Affirmed; Outlook Positive |
| May 29 |
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer |
| May 29 |
Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction |
| May 29 |
Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection |
| May 29 |
Ore Pharmaceuticals Inc. Announces NASDAQ Deficiency Notice |
| May 29 |
Gloucester Pharmaceuticals to Present New Data from Two Studies on Romidepsin at ASCO |
| May 29 |
Change in the Number of Shares in Vitrolife AB (publ) |
| May 29 |
NPS Reports Three Teduglutide Abstracts Accepted for Presentation at Digestive Disease Week Conference |
| May 29 |
Vion Pharmaceuticals to Present Data on Onrigin at the ASCO Annual Meeting |
| May 29 |
Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO |
| May 29 |
Biothera Releases Colorectal Cancer Study Results at ASCO |
| May 29 |
YM Biosciences Announces Results Of Randomized Nimotuzumab Study To Be Presented In A Poster At ASCO Annual Meeting |
| May 29 |
New Study Results Verify That PNH Cells Are Found in Majority of Patients with Bone Marrow Failure Syndromes |
| May 29 |
Novo Nordisk: New study directly comparing insulin delivery devices shows that Next Generation FlexPen® has a significantly lower injection force than SoloStar® and KwikPen® |
| May 29 |
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer |
| May 29 |
Pfizer Invites Public to View and Listen to Webcast of June 12 Conference Call with Analysts at EULAR |
| May 29 |
AV-951 Demonstrates Prolonged Progression-Free Survival and Excellent Safety Profile in Patients with Advanced Kidney Cancer; Phase 2 Data Presented at ASCO |
